Regeneron Pharmaceuticals Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.88 (market cap $76.14B), while Direxion Daily Semiconductor Bear 3X Shares trades at $34.56 (market cap $1.96B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 38.8× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.
| REGN | SOXS | |
|---|---|---|
Market Cap | $76.14B | $1.96B |
Volume | 500,239 | 113,512,541 |
Sector | Health | Leveraged / Inverse |
52-Week High | $852.03 | $988.00 |
52-Week Low | $557.73 | $29.62 |
Typical Hold Time | 107 Days | 11 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
SOXS, a leveraged inverse ETF tracking the semiconductor sector, trades at $34.12, up 11.34% over 24 hours amid recent semiconductor stock weakness. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. The fund executed a 1:10 stock split in July 2026 and has a dividend scheduled for September 2026. News highlights focus on volatility and tactical use, with articles noting surges during chip sell-offs.
The outlook for SOXS remains highly speculative, suitable only for short-term tactical trades due to its leveraged inverse structure and extreme volatility. Key risks include rapid erosion from semiconductor sector rebounds and structural decay. Investors should avoid long-term holdings, as persistent AI demand could trigger sharp losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →